title: Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma.
abstract: We analyzed the clinicopathological features of 9 breast malignant fibrous histiocytoma (MFH) patients. Immunohistochemistry was used to make both diagnosis and differential diagnosis, and to identify prognostic factors. All tumors lacked epithelial markers but expressed mesenchymal markers, suggesting a mesenchymal origin. Of the five cases expressing Ki-67, two of three patients with axillary lymph node involvement died between 6-8 months, and two died at 17 and 26 months after diagnosis. The two remaining cases, with low Ki-67 expression, had no recurrent or metastatic disease at 145 months after diagnosis. Previous studies have shown that surgery is the primary treatment of choice, but no clear benefit from adjuvant chemotherapy was observed. We demonstrate that axillary lymph node involvement and high expression of Ki-67 are associated with poorer prognosis. A literature review indicates surgery remains the first choice for MFH, but benefits from adjuvant chemotherapy remain unclear.
authors: 1] The Breast Center, Cancer Hospital of Shantou University Medical College, Guangdong, China [2].
authors: Si-Qi
authors: SQ
authors: Qiu
authors: Xiao-Long
authors: XL
authors: Wei
authors: Wen-He
authors: WH
authors: Huang
authors: Ming-Yao
authors: MY
authors: Wu
authors: Yun-Sheng
authors: YS
authors: Qin
authors: Yang-Kang
authors: YK
authors: Li
authors: Guo-Jun
authors: GJ
authors: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055815:Young Adult; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000737:chemistry / Q000175:diagnosis / Q000601:surgery; D051677:Histiocytoma, Malignant Fibrous / Q000737:chemistry / Q000175:diagnosis / Q000601:surgery; D019394:Ki-67 Antigen / Q000032:analysis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen
references: Cancer. 1990 Sep 1;66(5):941-4
references: 2386920
references: Eur J Gynaecol Oncol. 1985;6(2):105-8
references: 2992985
references: Cancer. 1948 May;1(1):3-29
references: 18867438
references: Eur J Surg Oncol. 1995 Apr;21(2):210-1
references: 7720902
references: World J Surg Oncol. 2011 Oct 17;9:131
references: 22004841
references: Clin Radiol. 2001 Jan;56(1):22-9
references: 11162693
references: Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3325-30
references: 19064546
references: Breast Cancer Res Treat. 2002 Feb;71(3):193-202
references: 12002339
references: J Surg Oncol. 1987 Jan;34(1):32-5
references: 3027458
references: Am J Surg. 2003 Oct;186(4):359-61
references: 14553850
references: Am J Surg Pathol. 1992 Jul;16(7):667-74
references: 1326897
references: Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):361-7
references: 1648044
references: Cases J. 2008 Nov 17;1(1):313
references: 19014612
references: Anticancer Res. 2005 Jan-Feb;25(1B):505-8
references: 15816619
references: Pathol Oncol Res. 2012 Jan;18(1):33-41
references: 21671140
references: Yonsei Med J. 2011 Jan;52(1):89-97
references: 21155040
references: Cancer. 1978 Jun;41(6):2250-66
references: 207408
references: Cancer. 1964 Nov;17:1445-55
references: 14223761
references: Acta Cytol. 2010 Sep-Oct;54(5 Suppl):985-8
references: 21053583
references: Int Surg. 1990 Jan-Mar;75(1):63-6
references: 2156782
references: Surgery. 1994 Sep;116(3):505-9
references: 8079181